Tressa Cochran
Nurse Practitioner · Belpre, OHNPI 1124095740
Payments from drug & device makers
Across 436 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- AstraZeneca$928
- Lilly USA, LLC$601
- Amgen$573
- Bayer$543
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,878100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 101 | $1,584 |
| Novo Nordisk | 61 | $1,099 |
| AstraZeneca | 39 | $928 |
| Lilly USA, LLC | 32 | $601 |
| Amgen | 38 | $573 |
| Bayer | 20 | $543 |
| Boehringer Ingelheim | 23 | $471 |
| Pfizer | 18 | $273 |
| Kowa Pharmaceuticals America, Inc. | 11 | $160 |
| Otsuka America Pharmaceutical, Inc. | 5 | $155 |
| Mylan Specialty L.p. | 9 | $152 |
| Lundbeck LLC | 8 | $149 |
| GSK | 9 | $142 |
| Amarin Pharma, Inc. | 12 | $140 |
| Astellas Pharma US Inc | 8 | $116 |
| Corcept Therapeutics | 1 | $114 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $104 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $99 |
| Merck | 4 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Axsome Therapeutics, Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| Johnson & Johnson | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Upsher-smith Laboratories LLC | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Novartis | 1 | $16 |
| Averitas Pharma Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,878 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $108,317 |
| Enbrel SureclickEtanercept | 11 | $80,335 |
| JardianceEmpagliflozin | 58 | $48,501 |
| FarxigaDapagliflozin Propanediol | 35 | $35,242 |
| MounjaroTirzepatide | 23 | $24,184 |
| Repatha SureclickEvolocumab | 21 | $22,818 |
| EliquisApixaban | 21 | $18,999 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $11,317 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $10,938 |
| VascepaIcosapent Ethyl | 18 | $8,378 |
| JanuviaSitagliptin Phosphate | 13 | $8,269 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 15 | $4,780 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $4,527 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,284 |
| Gabapentin | 126 | $2,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,099 | $108,31782 claims |
| Boehringer IngelheimJardiance | $471 | $48,50158 claims |
| AstraZenecaFarxiga | $928 | $35,24235 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy | $142 | $27,03545 claims |
| Lilly USA, LLCMounjaro | $601 | $24,18423 claims |
| PfizerEliquis | $273 | $18,99921 claims |
| MerckJanuvia | $60 | $8,26913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Belpre
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.